Hung Trinh: A Real-World Experience in Pan-Tumor Testing for HER2 INH in More Than 65 000 Solid Tumors
Hung Trinh, Senior Director of Business Development at OBiO Tech and Senior VP of Operations at Seneca Therapeutics, shared a post on LinkedIn:
“A Real-World Experience in Pan-Tumor Testing for HER2 IHC in More Than 65 000 Solid Tumors
Trastuzumab deruxtecan-nxki (T-DXd) was approved on April 5, 2024, by the US Food and Drug Administration for adults with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)–positive (immunohistochemistry [IHC] 3+) solid tumors who received systemic treatment and have no alternative treatment options.
1 This tumor-agnostic approval was based on the objective response rate and duration of response in 192 patients with HER2 IHC 3+ tumors in 1 of 3 clinical trials (DESTINY-PanTumor02, DESTINY-Lung01, DESTINY-CRC02).
Subtypes included colorectal (n = 64), bladder (n = 27), biliary tract (n = 22), lung (n = 17), endometrial (n = 16), ovarian (n = 15), cervical (n = 10), pancreatic (n = 5), and other tumors (n = 16).
2 This study hypothesized that HER2 IHC 3+ prevalence would vary across tumor types within a real-world setting. Results are from a cohort of more than 65 000 patients with solid tumors who underwent pan-tumor HER2 IHC testing since the approval.”
Title: A Real-World Experience in Pan-Tumor Testing for HER2 IHC in More Than 65 000 Solid Tumors
Authors: Dave Bryant, Rebecca Feldman, Farah Abdulla, Daniel Magee, Jennifer R. Ribeiro, Matthew Oberley, Milan Radovich, David Spetzler, George W. Sledge
More posts featuring Hung Trinh on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023